Cargando…

Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer

BACKGROUND: Hematuria following prostate radiotherapy is a known toxicity that may adversely affect a patient’s quality of life. Given the higher dose of radiation per fraction using stereotactic body radiation therapy (SBRT) there is concern that post-SBRT hematuria would be more common than with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gurka, Marie K, Chen, Leonard N, Bhagat, Aditi, Moures, Rudy, Kim, Joy S, Yung, Thomas, Lei, Siyuan, Collins, Brian T, Krishnan, Pranay, Suy, Simeng, Dritschilo, Anatoly, Lynch, John H, Collins, Sean P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358866/ https://www.ncbi.nlm.nih.gov/pubmed/25890265 http://dx.doi.org/10.1186/s13014-015-0351-6

Ejemplares similares

Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
por: Chen, Leonard N, et al.
Publicado: (2014)

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3))
por: Janowski, Einsley, et al.
Publicado: (2014)

Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer
por: Arscott, W Tristram, et al.
Publicado: (2014)

Clinical Characteristics and Management of Late Urinary Symptom Flare Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Woo, Jennifer A., et al.
Publicado: (2014)

Proctitis following stereotactic body radiation therapy for prostate cancer
por: Joh, Daniel Y, et al.
Publicado: (2014)

Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer
por: Bhattasali, Onita, et al.
Publicado: (2014)

Improved Irritative Voiding Symptoms 3 Years after Stereotactic Body Radiation Therapy for Prostate Cancer
por: Rana, Zaker, et al.
Publicado: (2014)

Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
por: Woo, Jennifer Ai-Lian, et al.
Publicado: (2015)

Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience
por: Chen, Leonard N, et al.
Publicado: (2013)

Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)
por: Pepin, Abigail, et al.
Publicado: (2020)

Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer
por: Bhattasali, Onita, et al.
Publicado: (2013)

Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction
por: Repka, Michael C., et al.
Publicado: (2016)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Janowski, Einsley-Marie, et al.
Publicado: (2015)

Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design
por: Paydar, Ima, et al.
Publicado: (2016)

Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
por: Aghdam, Nima, et al.
Publicado: (2020)

Potency preservation following stereotactic body radiation therapy for prostate cancer
por: Obayomi-Davies, Olusola, et al.
Publicado: (2013)

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
por: Aghdam, Nima, et al.
Publicado: (2020)

Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging
por: Paydar, Ima, et al.
Publicado: (2015)

Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer
por: Sood, Sumit, et al.
Publicado: (2013)

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience
por: Mercado, Catherine, et al.
Publicado: (2016)

Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT)
por: Shah, Sarthak, et al.
Publicado: (2023)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013)

Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer
por: Oermann, Eric K, et al.
Publicado: (2011)

Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy
por: Lei, Siyuan, et al.
Publicado: (2011)

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity
por: Paydar, Ima, et al.
Publicado: (2017)

Utilization of Iodinated SpaceOAR Vue™ During Robotic Prostate Stereotactic Body Radiation Therapy (SBRT) to Identify the Rectal–Prostate Interface and Spare the Rectum: A Case Report
por: Conroy, Dylan, et al.
Publicado: (2021)

Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer
por: Danner, Malika, et al.
Publicado: (2017)

Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Pepin, Abigail, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma
por: Gurka, Marie K., et al.
Publicado: (2017)

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer
por: Aghdam, Nima, et al.
Publicado: (2020)

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
por: Kataria, Shaan, et al.
Publicado: (2017)

Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation
por: Repka, Michael C., et al.
Publicado: (2017)

Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
por: Pepin, Abigail, et al.
Publicado: (2021)

Fiducial-free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body metastases: acceptable local control and normal tissue tolerance with 5 fraction approach
por: Gill, Beant, et al.
Publicado: (2012)

Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors
por: Kress, Marie-Adele S, et al.
Publicado: (2012)

The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Koneru, Harsha, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy for Liver Metastases from Colorectal Cancer: Analysis of Safety, Feasibility, and Early Outcomes
por: Kress, Marie-Adele S., et al.
Publicado: (2012)

Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases
por: Lischalk, Jonathan W., et al.
Publicado: (2016)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
por: Pepin, Abigail N., et al.
Publicado: (2022)

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Shah, Sarthak, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5jfkgrp0jhp9ug7dlqjcj1fkba